CM9521s Influenza Vaccine
Fusion Clinical Research is trialling a potential new seasonal influenza vaccine using mRNA technology, and we would like you to help us!
Seasonal influenza (otherwise known as the Flu) is a virus that causes the respiratory illness of the same name. Every year, seasonal influenza causes 3 to 5 million cases of severe illness and up to 650,000 deaths worldwide. Seasonal influenza generally affects people 65 years of age and older more severely but can adversely affect people of all ages.
Current seasonal influenza vaccines are usually only up to 60% effective. This trial involves mRNA-based flu vaccine to see if it is effective.
- Age: 50+
- Sex: Males & Females
- Medication: Exclusionary Criteria: – systemic immunosuppressants/immune-modifying drugs for >14 days in total within 180 days prior to enrolment – seasonal influenza vaccine within 180 days prior to enrolment – any vaccine within 28 days prior to enrolment – systemic immunoglobulins/blood products within 90 days prior to enrolment
- Medical History: Exclusionary Criteria: – pregnant or planning on becoming pregnant during participation – history of immunodeficiency, immunocompromising/immunosuppressive condition – reported history of anaphylaxis/severe hypersensitivity to all or part of an mRNA or influenza vaccine (inc egg protein) – positive influenza test result within 180 days of enrolment – myocarditis, pericarditis or myopericarditis within 60 days prior to enrolment
- $250 for the initial screening/dosing visit + $125 per visit thereafter
How to apply
To register your interest in this trial, please complete this form. A Fusion team member will be in contact to discuss your eligibility shortly.